Cagrilintide

2mg

$75.00

Cagrilintide is an investigational, long-acting amylin analogue developed by Novo Nordisk to treat obesity and type 2 diabetes by mimicking the hormone amylin to reduce appetite and induce satiety. It is commonly paired with semaglutide (known as CagriSema) in phase 3 trials, showing significant weight loss results—potentially over 15%—as a weekly injection.

Key Details About Cagrilintide

Mechanism: As a non-selective amylin and calcitonin receptor agonist, it works by delaying gastric emptying and acting on brain regions to reduce food intake.
Combination Therapy (CagriSema): The combination of 2.4 mg cagrilintide and 2.4 mg semaglutide is being tested to provide superior weight loss compared to existing therapies.

Weight Loss Efficacy: Studies indicate that about 31.6% of participants in trials achieved 15% or more weight loss, losing roughly 27.5 pounds on average.

Side Effects: Similar to other GLP-1/amylin agents, common side effects include gastrointestinal issues like nausea, vomiting, and diarrhea.

Status: As of mid-2026, it is an investigational drug undergoing Phase 3 trials (such as the REDEFINE studies) and is not yet available for general prescription.

Research Use Only

All products are intended strictly for laboratory research purposes only.

No Medical Claims

We do NOT claim: